The FDA 9/9 letters reshaped DTC advertising. Three months later the real impact is emerging, from ad pauses to pushback on net impression claims. On September 9 the FDA issued 27 untitled letters to pharma companies over allegedly misleading television ads. We reviewed what has actually happened to the DTC efforts of those cited brands. […]
“When you talk to a doctor or a lawyer, there's medical privileges, legal privileges. There's no current concept of that when you talk to an AI, but maybe there should be.” —Sam Altman, The Atlantic (2024) Take it from the CEO of OpenAI: Confidentiality and privacy protections are among the biggest unresolved issues for those […]
If the FDA’s targeting of TV ads and social media influencers makes one thing clear, it’s that the biopharma industry is under the microscope. Promotions once considered “safe” are now fair game for untitled letters, warning letters and cease-and-desists. Understanding this new environment matters, but it is not the real story. The real story is […]
To build trust and relevance, and achieve better outcomes, life science companies must embrace cocreation early, often, and intentionally. After being told she had metastatic breast cancer, Jackie* was devastated. Was this the end of the road then? What about her kids, her husband? There was little energy left in the tank but she saw […]
